ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 0513 • ACR Convergence 2021

    Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood

    DeAnna Diaz1, Thomas Vazquez2, Christina Bax3, Jay Patel4, Madison Grinnell5, Emily Keyes6, Yubin Li5 and Victoria Werth7, 1Philadelphia College of Medicine, Philadelphia, PA, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, 4Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 5Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 6Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
  • Abstract Number: 0713 • ACR Convergence 2021

    MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients

    Eveline Van Gompel1, Catia Cerqueira2, Karine Chemin3, Begum Horuluoglu1, Angeles Shunashy Galindo-Feria4, khaled amara5, Edvard Wigren6, Susanne Gräslund6, Ellen De Langhe7, Olivier Benveniste8 and Ingrid E Lundberg6, 1Karolinska Institutet, Stockholm, Sweden, 24Dcell, Montreuil, France, 3Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 4Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, 7KU Leuven, Leuven, Belgium, 8UPMC, Paris, France

    Background/Purpose: The presence of anti-melanoma differentiation associated protein 5 (MDA5) autoantibodies in myositis patients is associated with mucocutaneous ulcerations, (rapidly progressing) interstitial lung disease (RPILD),…
  • Abstract Number: 0684 • ACR Convergence 2021

    Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy

    Yoshiyuki Abe1, Masahiro Kogami2, Makio Kusaoi2, Kurisu Tada3, Ken yamaji4 and Naoto Tamura3, 1Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo University, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 4Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan

    Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
  • Abstract Number: 0714 • ACR Convergence 2021

    Diagnostic Accuracy of Electromyogram for Myositis

    Lois bolko1, Sarah Leonard Louis2, Jean hugues Salmon1, Olivier Benveniste3, Yves Allenbach3 and Thierry Maisonobe4, 1Rheumatology, CHU maison blanche, Reims, Reims, France, 2Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, 3Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, 4Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France

    Background/Purpose: The skeletal muscle biopsy is the gold standard for idiopathic inflammatory myopathies (IIM) diagnosis. Myositis specific antibodies are diagnostic biomarkers for IIM but are…
  • Abstract Number: 0687 • ACR Convergence 2021

    Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis

    Christopher Mecoli1, Eleni Tiniakou2, William Kelly2, Jemima Albayda2, Julie Paik2, Brittany Adler2, Andrew Mammen3, Cheng Ting Lin1, Sonye Danoff4, Livia Casciola-Rosen5 and Lisa Christopher-Stine2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3National Institutes of Health, Bethesda, MD, 4Johns Hopkins Medicine, Baltimore, MD, 5Johns Hopkins, Baltimore, MD

    Background/Purpose: We describe a single-center North American adult cohort of MDA5-positive DM, with emphasis on the subgroup of patients that experience drug-free long-term remission. Methods:…
  • Abstract Number: 0719 • ACR Convergence 2021

    Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies

    Gözde Kübra Yardımcı1, Arzu Taghiyeva2, Enes Erul2, Bayram Farisogulları3, Levent Kilic1 and Sule Apraş Bilgen1, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2HACETTEPE UNIVERSITY, Ankara, Turkey, 3Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
  • Abstract Number: 0688 • ACR Convergence 2021

    Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis

    Christopher Mecoli1, Takeru Igusa2, Mengkun Chen3, XingYao Wang2, Jemima Albayda2, Julie Paik2, Eleni Tiniakou2, Brittany Adler2, Carrie Richardson4, William Kelly2, Sonye Danoff5, Andrew Mammen6, Elizabeth Platz3, Antony Rosen2, Lisa Christopher-Stine2, Livia Casciola-Rosen7 and Ami Shah8, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins School of Public Health, Baltimore, MD, 4Rush University Medical Center, Chicago, IL, 5Johns Hopkins Medicine, Baltimore, MD, 6National Institutes of Health, Bethesda, MD, 7Johns Hopkins, Baltimore, MD, 8Johns Hopkins Rheumatology, Baltimore, MD

    Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…
  • Abstract Number: 0720 • ACR Convergence 2021

    The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients

    Yuji Hosono1, Azusa Kojima1, Akira Ishii1, Yuto Izumi1, Kazuki Hirano1, Noriko Sasaki2, Chiho Yamada1 and Shinji Sato3, 1Tokai University School of Medicine, Isehara, Japan, 2tokai university, sagamihara-city, Japan, 3Tokai University, Isehara, Japan

    Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
  • Abstract Number: 0689 • ACR Convergence 2021

    Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort

    Vanessa Kronzer1, Bradly Kimbrough2, Cynthia Crowson3, John Davis1, Marie Holmqvist4 and Floranne Ernste1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan & Peter 1975 criteria, and most were not population-based.…
  • Abstract Number: 0756 • ACR Convergence 2021

    Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis

    R Naveen1, Darpan R Thakare2, Vikas Agarwal2, Rohit Aggarwal3 and Latika Gupta1, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
  • Abstract Number: 0695 • ACR Convergence 2021

    Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    Rohit Aggarwal1, Christina Charles-Schoeman2, Joachim Schessl3, Zsuzsanna Bata-Csorgo4, Mazen Dimachkie5, Zoltan Griger6, Sergey Moiseev7, Chester Oddis1, Elena Schiopu8, Jiri Vencovsky9, Irene Beckmann10, Elisabeth Clodi10, Todd Levine11 and and the ProDERM Investigators12, 1University of Pittsburgh, Pittsburgh, PA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Friedrich-Baur-Institut/Medical University Munich, München, Germany, 4University of Szeged, Faculty of Medicine, Szeged, Hungary, 5University of Kansas Medical Center, Kansas City, KS, 6University of Debrecen, Debrecen, Hungary, 7First Moscow State Medical University, Moscow, Russia, 8University of Michigan, Ann Arbor, MI, 9Institute of Rheumatology, Prague, Czech Republic, 10Octapharma PPG, Vienna, Austria, 11Phoenix Neurological Associates, LTD, Phoenix, AZ, 12Different Institutions in several countries, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with characteristic skin rash and muscle weakness. Intravenous immunoglobulin (IVIg) has long been used as adjuvant…
  • Abstract Number: 0766 • ACR Convergence 2021

    Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort

    Jessica Neely1, Kaveh Ardalan2, Adam Huber3 and Susan Kim4, 1University of California San Francisco, San Francisco, CA, 2Duke University Medical Center, Durham, NC, 3Dalhousie University, Halifax, NS, Canada, 4UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
  • Abstract Number: 0696 • ACR Convergence 2021

    Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study

    Lara Dani1, Sandra Selickaja2, Angeles Shunashy Galindo-Feria3, John Svensson4, Paulius Venalis5, Dag Leonard6, Malin Hemberg7, Balsam Hanna8, Ingrid E Lundberg9 and Marie Holmqvist4, 1Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 2State Research Institute for Innovative Medicine and Vilnius university hospital Santaros Klinikos, Vilnius, Lithuania, 3Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Department of Rheumatology, Uppsala University, Uppsala, Sweden, 7Rheumatology Unit, Falu Lasarett, Falun, Sweden, 8Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, 9Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: To longitudinally follow the levels of anti- transcriptional intermediary factor (TIF)1-gamma autoantibodies in patients with dermatomyositis with and without cancer.Methods: We identified sera from…
  • Abstract Number: 0773 • ACR Convergence 2021

    Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis

    Hanna Kim1, Ly-Lan Bergeron2, Samantha Dill2, MIchelle O'Brien2, Xiaobai Li3, Jomy George3, April Brundidge2, Michelle Millwood2, Lisa Rider4 and Robert Colbert5, 1Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, 2Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, 3Clinical Center, National Institutes of Health, Bethesda, MD, 4NIEHS, NIH, Garrett Park, MD, 5NIH/NIAMS, Bethesda, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
  • Abstract Number: 0699 • ACR Convergence 2021

    Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review

    Lilian Vilar, William Moore and Ian Ward, Dwight D Eisenhower Army Medical Center, Fort Gordon

    Background/Purpose: The Idiopathic Inflammatory myopathies (IIM) are characterized by muscle damage and progressive weakness. Myoglobin is not typically released in high levels in IIM and…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology